Annuncio • Jun 12
Porvair plc to Report Fiscal Year 2026 Results on Feb 08, 2027 Porvair plc announced that they will report fiscal year 2026 results on Feb 08, 2027 Annuncio • May 20
Richard Bernstein Calls for Sale of Porvair On May 19, 2026, Richard Bernstein, founder and former investment manager of Crystal Amber, announced that he is reportedly calling for a sale of Porvair plc. Richard Bernstein stated that he has written to the Company’s chairman John Nicholas urging him to explore strategic alternatives for the Company. Richard Bernstein said that the Company was an attractive business currently valued by the stock market at substantially below its strategic value. Annuncio • Apr 16
Porvair plc Approves Final Dividend Porvair plc at its AGM held on April 14, 2026, approved final dividend of 4.5 pence per ordinary share. Annuncio • Feb 11
Porvair plc Recommends Final Dividend, Payable on 8 June 2026 The Directors of Porvair plc recommend the payment of a final dividend of 4.5 pence per share (2024: 4.2 pence per share) to be paid on 8 June 2026 to shareholders on the register on 1 May 2026; the ex-dividend date is 30 April 2026. This makes a total dividend for the year of6.7pence per share (2024: 6.3 pence per share). Annuncio • Feb 10
Porvair plc, Annual General Meeting, Apr 14, 2026 Porvair plc, Annual General Meeting, Apr 14, 2026. Location: the offices of burson buchanan, rose court, 2 southwark bridge road, se1 9hs, london United Kingdom Annuncio • Feb 09
Porvair plc to Report First Half, 2026 Results on Jun 29, 2026 Porvair plc announced that they will report first half, 2026 results on Jun 29, 2026 Annuncio • Dec 16
Porvair plc Provides Earnings Guidance for the Year Ended 30 November 2025 Porvair plc provided earnings guidance for the year ended 30 November 2025. For the period, the Group expects revenue growth to be around 1% (2% at constant currency), with both operating profit and margin ahead of the prior year. Annuncio • Sep 27
Porvair plc Announces Board Changes Porvair plc announced that Lisa Anson has been appointed as Non-Executive Director of the Company with effect from 1 October 2025. Lisa is currently Chief Executive Officer of Redx Pharma limited, a UK based, privately held clinical-stage biotech business; a position she held when Redx was publicly listed on AIM. In addition, she is a Supervisory Board Member for Apoplex Medical Technologies GmBH, a private German company and is an elected Board Member of the UK BioIndustry Association (BIA). She was previously a Board Member and then Chair at the Association of the British Pharmaceutical Industry (ABPI). Lisa's career spans almost 30 years in the pharmaceutical and Biotech industry including more than twenty years at AstraZeneca Plc. She has extensive global leadership and commercial experience, including several USA based roles and most recently was Country President for the UK and Ireland. On appointment, Lisa will join the Audit Committee, Remuneration Committee and Nomination Committee of Porvair. Having completed 9 years as a Non-Executive Director at Porvair, Sally Martin will retire from the Board on 4 November 2025. Following Sally's retirement, Sheena Mackay will be appointed Senior Independent Director of the Board and the Non-Executive Director responsible for employee engagement, in addition to her role as Chair of the Remuneration Committee. Annuncio • Jun 30
Porvair plc Declares an Interim Dividend, Payable on 22 August 2025 The Directors of Porvair plc have declared an interim dividend of 2.2 pence (2024: 2.1 pence) per share to be paid on 22 August 2025 to shareholders on the register at the close of business on 18 July 2025; the ex-dividend date is 17 July 2025. Annuncio • Jun 20
Porvair plc to Report Fiscal Year 2025 Results on Feb 09, 2026 Porvair plc announced that they will report fiscal year 2025 results on Feb 09, 2026 Annuncio • Apr 17
Porvair plc Announces Change of Remuneration Committee Chair, Effective April 15, 2025 Porvair plc announced that Sheena Mackay has succeeded Sally Martin as Chair of the Remuneration Committee with effect from 15 April 2025. Sally will continue to be the Senior Independent Director and a member of the Remuneration Committee, Nomination Committee and Audit Committee. Sally retains her responsibilities as the designated Director responsible for Employee Engagement. Sheena joined the Board on 28 October 2024 as a Non-Executive Director and has been a member of the Remuneration Committee, Nomination Committee and Audit Committee since her appointment. Sheena is also a Non-Executive Director of Lords Group Trading plc, an Aim listed building material distributor, where she is Chair of the Remuneration Committee and Nomination Committee and a member of the Audit Committee. Annuncio • Feb 10
Porvair plc to Report First Half, 2025 Results on Jun 30, 2025 Porvair plc announced that they will report first half, 2025 results on Jun 30, 2025 Annuncio • Oct 28
Porvair plc Announces Appointment of Sheena Mackay as an Independent Non-Executive Director and Joins Its Audit Committee, Remuneration Committee and Nomination Committee Porvair plc announced the appointment of Sheena Mackay as an Independent Non-Executive Director of the Company with effect from 28 October 2024. Sheena is a Non-Executive Director of Lords Group Trading plc, an Aim listed building material distributor, where she is Chair of the Remuneration Committee and Nomination Committee and a member of the Audit Committee. Sheena was a Non-Executive Director at Foxtons Group plc, the London based estate agency, from 2017 to 2023. Sheena's executive career spans more than 30 years in human capital management. Sheena was Group Human Resources Director for Smiths Group plc, a FTSE 100 global industrial technology company, between 2016 and 2022. Prior to Smiths, Sheena was Group Human Resources Director at Aggreko plc, a global supplier of temporary power and temperature control equipment, BBA Aviation plc, a multinational aviation services company, and SSL International Group plc, a multinational manufacturer and supplier of healthcare products. Prior to SSL Sheena's early career was at the General Electric Company plc, a global FTSE 100 industrial conglomerate. On appointment, Sheena will join the Audit Committee, Remuneration Committee and Nomination Committee. Annuncio • Jul 01
Porvair plc Declares Interim Dividend, Payable on 21 August 2024 The Directors of Porvair plc have declared an interim dividend of 2.1 pence (2023: 2.0 pence) per share to be paid on 21 August 2024 to shareholders on the register at the close of business on 19 July 2024; the ex-dividend date is 18 July 2024. Annuncio • May 25
Porvair plc to Report Fiscal Year 2024 Results on Feb 10, 2025 Porvair plc announced that they will report fiscal year 2024 results on Feb 10, 2025 Annuncio • Apr 03
Porvair plc Announces Resignation of Sarah Vawda as Director Porvair plc announces that Sarah Vawda resigned from the Board with immediate effect. a consequence of Sarah's resignation, AGM Resolution 10 "To elect Sarah Vawda as a Director" will be withdrawn from the resolutions to be put to the Company's AGM on 16 April 2024. Annuncio • Sep 07
Porvair plc, Annual General Meeting, Apr 16, 2024 Porvair plc, Annual General Meeting, Apr 16, 2024. Annuncio • Jul 04
Porvair plc Declares an Interim Dividend, Payable on 23 August 2023 Porvair plc announced the Directors have declared an interim dividend of 2.0 pence (2022: 1.9 pence) per share to be paid on 23 August 2023 to shareholders on the register at the close of business on 21 July 2023; the ex-dividend date is 20 July 2023. Annuncio • Jun 27
Porvair plc Announces Appointment of Sarah Vawda as an Independent Non-Executive Director of the Company Porvair plc announced the appointment of Sarah Vawda as an independent Non-Executive Director of the Company with effect from 26 June 2023. Sarah is the Senior Independent Non-Executive Director and Chair of the Audit Committee of Access Intelligence plc, an AIM listedreputation management, marketing and communications,software as a service business; Non-Executive Director of Hamlet Protein A/S, a private equity backed Danish specialty protein business; and Non-Executive Director and Chair of the Remuneration and Nomination Committees ofNoveltech Private Feeds Ltd. (India),a private equity backed Indian animal nutrition business. She was formerly Non-Executive Director and Chair of the Audit and Risk Committees at Burger King UK; Trustee and Chair of the Audit Committee at The Girls Network; and Governor of the University of Bedfordshire. Sarah has previously held senior executive roles within Global multinational companies including Powergen Plc, Corus Group plc, Christian Salvesen plc, Provimi SA and Johnson Matthey plc. She qualified as a chartered accountant with PwC. On appointment, Sarah will join the Audit Committee, Remuneration Committee and Nominations Committee of Porvair plc. Annuncio • Jun 24
Porvair plc to Report Fiscal Year 2023 Results on Jan 29, 2024 Porvair plc announced that they will report fiscal year 2023 results on Jan 29, 2024 Annuncio • May 06
Porvair plc (LSE:PRV) acquired Business and Assets of HRW Inc. Porvair plc (LSE:PRV) acquired Business and Assets of HRW Inc. on March 3, 2023.Porvair plc (LSE:PRV) completed the acquisition of Business and Assets of HRW Inc. on March 3, 2023. Annuncio • May 05
Porvair plc (LSE:PRV) agreed to acquire 100% stake in Ratiolab GmbH and Ratiolab Kft. Porvair plc (LSE:PRV) agreed to acquire 100% stake in Ratiolab GmbH and Ratiolab Kft. on May 4, 2023. Regulatory approval is expected to take around three months. Ratiolab has annual external revenues of around €12 million. Sally Sha, Ralf Hoffman, Jürgen Wohlfart and John Kim of EC Mergers & Acquisitions acted as exclusive financial advisor to Ratiolab. Annuncio • Jan 31
Porvair plc to Report First Half, 2023 Results on Jul 03, 2023 Porvair plc announced that they will report first half, 2023 results on Jul 03, 2023 